MDR-TB

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with OBR for MDR-TB in HIV-Infected and Uninfected Children with MDR-TB

Post Date: 
2018-06-07
   |   
Countries: 
   |   
Clinical Sites: 
New study will characterize the pharmacokinetics of delamanid using a model-based approach, and evaluate safety and tolerability of over 24 weeks of study treatment in HIV infected and uninfected children.

Tuberculosis Noon Conference

Post Date: 
2013-10-24
   |   
Countries: 
   |   
This effort ended in 2015. As part of the BJGMC-Johns Hopkins India Fogarty Training Program, from 2013-2015 CCGHE hosted the live Tuberculosis Noon Conference webcast. Led by Drs. Maunank Shah, Jonathan Golub, and Richard Chaisson, these webcast meetings brought together Johns Hopkins TB...

BJGMC-JHU Fogarty HIV-TB Training Program

Post Date: 
2007-01-01
   |   
Countries: 
   |   
Clinical Sites: 
Funded by the Fogarty International Center at the National Institutes of Health, the JHU Fogarty program has nearly 20 years of success with providing training, professional development, and mentorship to clinicians and scientists in low and middle income countries. CCGHE's latest efforts in...

Tuberculosis Pathways to Care and Transmission of Multidrug Resistance in India

Post Date: 
2022-01-15
   |   
Countries: 
Publication: 
American Journal of Respiratory Critical Care Medicine
Abstract Rationale: India is experiencing a regional increase in cases of multidrug-resistant tuberculosis (MDR-TB). Objectives: Given the complexity of MDR-TB diagnosis and care, we sought to address key knowledge gaps in MDR risk factors, care delays, and drivers of delay to help guide disease...

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons

Post Date: 
2019-08-15
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
PLOS Medicine
PLOS Medicine: Dr. Amita Gupta and colleagues discuss the scientific and ethical basis for including pregnant and lactation women, children, and HIV+ patients in tuberculosis therapeutic clinical trials.

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Post Date: 
2019-01-28
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
BMC Infectious Diseases
BACKGROUND: India has the world's highest tuberculosis burden, and Mumbai is particularly affected by multidrug resistant tuberculosis (MDR-TB). WHO recommends short, intensive treatment ("Short Course") for previously untreated pulmonary MDR-TB patients but does not require universal...

HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries

Post Date: 
2019-01-07
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
International Journal of Tuberculosis and Lung Disease : The Indo-JHU Clinical Research Parentership participated in this multinational study to determine if it's feasible to provide HIV testing for household contacts of MDR-TB cases.

MDR-TB in children: back to the basics

Post Date: 
2018-05-01
   |   
Countries: 
Publication: 
The International Journal of Tuberculosis and Lung Disease
IJTLD: Summary of the Pediatric Multidrug-Resistant Tuberculosis Clinical Trials Landscape Meeting: a primer of current directions.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

Post Date: 
2017-03-24
Publication: 
The Lancet Respiratory Medicine
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tuberculosis control has been effective in some regions of the world, these gains are threatened by the increasing...

Management and control of multidrug-resistant tuberculosis (MDR-TB): addressing policy needs for India

Post Date: 
2016-05-06
   |   
Countries: 
Publication: 
Journal of Public Health Policy
Multidrug-resistant tuberculosis (MDR-TB) challenges TB control efforts because of delays in diagnosis plus its long-term treatment which has toxic effects. Of TB high-incidence countries, India carries the highest burden of MDR-TB cases. We describe policy issues in India concerning MDR-TB...

Patterns of TB drug-resistance in a tertiary care facility in Pune, India

Post Date: 
2013-07-18
   |   
Countries: 
Publication: 
Clinical Microbiology
Introduction:Globally, the emergence of multi-drug resistant tuberculosis (MDRTB) (defined as resistance to isoniazid (INH) and rifampicin (RIF) and extensively drug resistant (XDR-TB) (defined as resistance to INH, RIF, any fluoroquinolone and to at least one of the three injectable second...

Tuberculosis in pregnant and postpartum women: Epidemiology, management, and research gaps

Post Date: 
2012-12-15
Publication: 
Clinical Infectious Diseases
Tuberculosis is most common during a woman's reproductive years and is a major cause of maternal-child mortality. National guidelines for screening and management vary widely owing to insufficient data. In this article, we review the available data on (1) the global burden of tuberculosis in...